Osteoclasts degrade mineralized bone matrix via releasing their lysosomes. However, the mechanisms underlying how lysosomal secretion is regulated in osteoclasts remain largely unknown. PLEKHM1 is a newly identified, causative gene of osteopetrosis in humans and incisors absent (ia/ia) rats. Plekhm1 deficient human and rat osteoclasts exhibit diminished resorptive activity with accumulation of intracellular lysosomes, suggesting that Plekhm1 is a critical regulator of intracellular lysosome trafficking and secretion in osteoclasts. Plekhm1 interacts with Rab7, a lysosome-associated small GTPase, through its C-terminal Rubicon homolog (RH) domain. Overexpression of full-length, but not RH domain-deleted mutant of Plekhm1 by retroviral transduction, rescues bone resorption defect in Plekhm1-/- osteoclasts. Moreover, RH domain-deleted mutant of Plekhm1 fails to be recruited to lysosomes by Rab7. These data led to the hypothesis that the binding of Plekhm1 RH domain to Rab7 plays an important role in regulating lysosome secretion and bone resorption in osteoclasts. The goals of this grant application are to elucidate the molecular details of Plekhm1 and rab7 interaction by crystallography and functional identification of critica residues on Plekhm1 RH domain mediating Rab7 binding. Therefore, we will pursue a) to identify the binding surface and key amino acids mediating the interaction of Plekhm1 RH domain and Rab7 (Aim1); b) to conduct structural-functional analysis of key amino acids in RH domain of Plekhm1 in lysosomal secretion and bone resorption in osteoclasts (Aim2).

Public Health Relevance

Aberrantly enhanced osteoclast activity causes bone loss and fractures, leading to major public health problems. We have identified two proteins in osteoclasts which work together to control osteoclast activity. We plan to determine how these proteins interact in osteoclasts, raising the possibility that we will be able to provide new therapeutic targets for the treatment of bone loss in metabolic bone diseases such as osteoporosis and arthritis.

Agency
National Institute of Health (NIH)
Institute
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Type
Exploratory/Developmental Grants (R21)
Project #
5R21AR068509-02
Application #
9226047
Study Section
Skeletal Biology Development and Disease Study Section (SBDD)
Program Officer
Alekel, D Lee
Project Start
2016-04-01
Project End
2018-03-31
Budget Start
2017-04-01
Budget End
2018-03-31
Support Year
2
Fiscal Year
2017
Total Cost
$147,510
Indirect Cost
$48,510
Name
University of Arkansas for Medical Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
122452563
City
Little Rock
State
AR
Country
United States
Zip Code
72205
Kiaei, Mahmoud; Balasubramaniam, Meenakshisundaram; Govind Kumar, Vivek et al. (2018) ALS-causing mutations in profilin-1 alter its conformational dynamics: A computational approach to explain propensity for aggregation. Sci Rep 8:13102
Wang, Lei; Fang, Bin; Fujiwara, Toshifumi et al. (2018) Deletion of ferroportin in murine myeloid cells increases iron accumulation and stimulates osteoclastogenesis in vitro and in vivo. J Biol Chem 293:9248-9264
Fujiwara, Toshifumi; Ye, Shiqiao; Castro-Gomes, Thiago et al. (2016) PLEKHM1/DEF8/RAB7 complex regulates lysosome positioning and bone homeostasis. JCI Insight 1:e86330
Ye, Shiqiao; Fujiwara, Toshifumi; Zhou, Jian et al. (2016) LIS1 Regulates Osteoclastogenesis through Modulation of M-SCF and RANKL Signaling Pathways and CDC42. Int J Biol Sci 12:1488-1499